CN110167558A - 三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途 - Google Patents

三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途 Download PDF

Info

Publication number
CN110167558A
CN110167558A CN201780078675.XA CN201780078675A CN110167558A CN 110167558 A CN110167558 A CN 110167558A CN 201780078675 A CN201780078675 A CN 201780078675A CN 110167558 A CN110167558 A CN 110167558A
Authority
CN
China
Prior art keywords
compound
disease
pharmaceutically acceptable
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078675.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·诺得瓦尔
P·福塞尔
J·桑丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azek Pharmaceutical Co
Original Assignee
Azek Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azek Pharmaceutical Co filed Critical Azek Pharmaceutical Co
Publication of CN110167558A publication Critical patent/CN110167558A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780078675.XA 2016-12-21 2017-12-21 三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途 Pending CN110167558A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1651706-2 2016-12-21
SE1651706 2016-12-21
PCT/GB2017/053868 WO2018115891A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
CN110167558A true CN110167558A (zh) 2019-08-23

Family

ID=60923799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078675.XA Pending CN110167558A (zh) 2016-12-21 2017-12-21 三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途

Country Status (12)

Country Link
US (1) US20200113910A1 (https=)
EP (1) EP3558320A1 (https=)
JP (1) JP2020502225A (https=)
KR (1) KR20190098982A (https=)
CN (1) CN110167558A (https=)
AU (1) AU2017380583A1 (https=)
BR (1) BR112019012709A2 (https=)
CA (1) CA3046289A1 (https=)
IL (1) IL267086A (https=)
MX (1) MX2019007606A (https=)
RU (1) RU2019120431A (https=)
WO (1) WO2018115891A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52415A (fr) 2018-02-26 2021-01-06 AlzeCure Pharma AB Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219552A (en) * 1977-04-27 1980-08-26 Bayer Aktiengesellschaft 1-(4-Phenoxy-phenyl)-1,3,5-triazines, their use as growth promoters
US20120196860A1 (en) * 2009-06-09 2012-08-02 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CN104529945A (zh) * 2009-12-11 2015-04-22 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219552A (en) * 1977-04-27 1980-08-26 Bayer Aktiengesellschaft 1-(4-Phenoxy-phenyl)-1,3,5-triazines, their use as growth promoters
US20120196860A1 (en) * 2009-06-09 2012-08-02 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CN104529945A (zh) * 2009-12-11 2015-04-22 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Also Published As

Publication number Publication date
IL267086A (en) 2019-08-29
RU2019120431A (ru) 2021-01-22
BR112019012709A2 (pt) 2019-11-26
JP2020502225A (ja) 2020-01-23
RU2019120431A3 (https=) 2021-03-09
CA3046289A1 (en) 2018-06-28
WO2018115891A1 (en) 2018-06-28
EP3558320A1 (en) 2019-10-30
US20200113910A1 (en) 2020-04-16
MX2019007606A (es) 2020-07-29
AU2017380583A1 (en) 2019-06-27
KR20190098982A (ko) 2019-08-23

Similar Documents

Publication Publication Date Title
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
US11498927B2 (en) Heterocyclic amide for inhibiting RIP1 kinase and uses thereof
US12065447B2 (en) Heterocyclic amide for inhibiting RIP1 kinase and uses thereof
CN110167558A (zh) 三嗪三酮衍生物及其作为神经营养素受体和受体酪氨酸激酶的调节剂的用途
CN103108633B (zh) TrkB激动剂及其用途
US20210214337A1 (en) Substituted alkoxypyridinyl indolsulfonamides
CA3147623A1 (en) Triazine derivatives for treating diseases relating to neurotrophins
CN115515682B (zh) 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
KR20210028649A (ko) Trk 수용체의 조절제로서의 4-치환된 페닐-1,3,5-트리아진 유도체
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
WO2024222837A1 (zh) 四氢萘基丙基氨甲基哌啶芳基（磺）酰胺衍生物、其制备方法和应用
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190823

WD01 Invention patent application deemed withdrawn after publication